Longeveron Inc

LGVNNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

No share count on file in the XBRL facts for this window.

Newest

$70.0M

S-3 of 2025-03-28. 1 prospectus supplement filed under it since. S-3 ↗

$10.7M

H.C. Wainwright, agreement of 2025-09-19. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

2.57M

Warrants of every class as tagged in the XBRL facts on 2024-08-12. 10-Q ↗

Cash

2 quarters

$10.1M on 2026-06-30 ÷ $5.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-03-12	Private placement	6,013,384	$0.52	not stated	8-K ↗
2025-08-08	Public offering	5,617,648	$0.85	$5.0M	424B4 ↗
2025-08-08	Private placement incl. 0.26M pre-funded	529,412	not read	$5.0M	8-K ↗

Also on file: a 1-for-2 reverse split, 2026-06-30 8-K ↗ · a 1-for-10 reverse split, 2026-08-20 8-K ↗